21,907 Shares in TG Therapeutics, Inc. $TGTX Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 21,907 shares of the biopharmaceutical company’s stock, valued at approximately $1,222,000.

A number of other large investors also recently modified their holdings of the business. Stronghold Wealth Management L.L.C. increased its holdings in TG Therapeutics by 6.3% in the 3rd quarter. Stronghold Wealth Management L.L.C. now owns 3,922 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 231 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of TG Therapeutics by 45.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 312 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 365 shares during the period. Choreo LLC lifted its position in shares of TG Therapeutics by 3.7% during the 3rd quarter. Choreo LLC now owns 10,811 shares of the biopharmaceutical company’s stock worth $603,000 after buying an additional 384 shares during the period. Finally, Chiron Capital Management LLC lifted its position in shares of TG Therapeutics by 10.5% during the 3rd quarter. Chiron Capital Management LLC now owns 4,200 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 400 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the sale, the director owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 8.87% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on TGTX. Weiss Ratings raised TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. HC Wainwright reissued a “buy” rating and set a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, September 1st. Zacks Research upgraded shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. Finally, B. Riley Financial boosted their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $63.00.

Read Our Latest Stock Report on TG Therapeutics

TG Therapeutics Price Performance

TGTX opened at $64.51 on Monday. The company has a fifty day moving average price of $56.69 and a two-hundred day moving average price of $45.33. The firm has a market capitalization of $9.75 billion, a PE ratio of 97.74, a P/E/G ratio of 5.08 and a beta of 1.89. TG Therapeutics, Inc. has a 52 week low of $26.76 and a 52 week high of $68.03. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.75 and a current ratio of 4.50.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.01). The company had revenue of $259.94 million during the quarter, compared to analyst estimates of $245.47 million. TG Therapeutics had a net margin of 11.81% and a return on equity of 18.82%. The business’s revenue for the quarter was up 60.8% compared to the same quarter last year. During the same period last year, the company earned $2.43 EPS. As a group, analysts anticipate that TG Therapeutics, Inc. will post 1.10 earnings per share for the current year.

About TG Therapeutics

(Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

See Also

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.